tbuckley/cabot-search huggingface dataset:
Second malignant neoplasm (SMN) in a cohort of early stage cancer survivors (ESCS) followed at Instituto Oncológico Henry Moore (IOHM) in the last 15 years.
Authors: Flavio Tognelli, Ernesto Gil Deza, Natasha Gercovich, Eduardo L. Morgenfeld, Edgardo G. J. Rivarola, Claudia Lorena Acuna, Dario Niewiadomski, Felipe G. Gercovich
Journal: Journal of Clinical Oncology (2016)

e13057 Background: The prolonged survival achieved when tumors are treated at early stages allows the diagnosis of a SMN in many patients during the follow up period.The following study aims to present the incidence of secondary tumors in a cohort of ESCS patients (Pt) followed at IOHM. Methods: A search of the IOHM database was carried out, looking for Pt that had been registered between 1/12/2000 and 1/6/2015 with early stage (0-I-II-III) tumors and had been followed for more than six months. Those with a SMN were identified. In all of these, the following was studied: Dx, detection (screening vs symptomatic), presentation (synchronic vs metachronic) and stage. Results: It was possible to find 12038 ESCS that met selection criteria. Population characteristics: Median age at Dx of primary tumor: 58 years (r 18-98y). Sex: male 4689 Pt (39%) / female 7335 Pt (61%). Median follow up was 40 months (r 6-183m). The table below shows primary tumors and most frequent SMN. In 476/556 Pt (86%), SMN was metachronic and in 474/556 Pt (85%) it was detected at early stages. In metachronic tumors the median interval between the first tumor and SMN was 34 months (r 1-179). Conclusions: 1) In a 12038 ESCS Pt cohort followed up at IOHM, 556 Pt with SMN were identified 2) The majority of SMN were metachronic and detected at early stages as a consequence of screening 3) Early detection of secondary tumors increases the curability rate. SMN incidence according to primary tumor Dx. First tumor SMN- Breast SMN- Colo- rectal SMN- Prostate SMN- Lung SMN- Bladder SMN- Kidney SMN- Ovarian SMN- Ohers SMN- Total Breast (n = 4371) 150 16 1 6 4 5 9 44 235 Others Gyn. (n = 1108) 13 5 0 2 2 0 1 14 37 Prostate (n = 1446) 1 9 0 7 7 9 0 18 51 Others Urol. (n = 1373) 0 4 13 11 2 3 0 13 46 Colo-rectal (n = 1453) 20 11 15 1 4 0 5 16 72 Others GI (n = 360) 4 1 2 2 2 0 1 4 16 Lung (n = 376) 3 1 4 0 1 1 1 10 21 NHL (n = 274) 1 1 1 1 0 0 0 5 9 Others Hem. (n = 365) 0 1 1 2 0 1 0 10 15 Other Primaries (n = 912) 7 4 5 8 3 4 0 23 54 Total (n = 12038) 199 53 42 40 25 23 17 157 556
The clinical merit of routine, preoperative staging of colorectal carcinoma by abdominopelvic computerised tomography
Authors: E Harris, RA Cahill, D O'Riordain, W Torreggiani, F Keane
Journal: Endoscopy (2006)

Aims: The utility of routine, preoperative abdominopelvic computerised tomogram (apCT) for patients with colorectal carcinoma is unclear. Here, we examine its worth.
VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas
Authors: Teresa Palomero, Francesco Abate, Ana Carolina da Silva Almeida, Sakellarios Zairis, Javier Robles-Valero, Lucile Couronne, Hossein Khiabanian, S Aidan Quinn, Mi-Yeon Kim, Maria Antonella Laginestra, Christine S Kim, Danilo Fiore, Govind Bhagat, Miguel Angel A. Piris, Elias Campo, Izidore S Lossos, Olivier A. Bernard, Giorgio Inghirami, Stefano A Pileri, Xose R Bustelo, Raul Rabadan, Adolfo A. Ferrando
Journal: Blood (2016)
Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression
Authors: Caroline Bonet, Flavie Luciani, Jean-François Ottavi, Justine Leclerc, Fanélie-Marie Jouenne, Marina Boncompagni, Karine Bille, Véronique Hofman, Guillaume Bossis, Gian Marco de Donatis, Thomas Strub, Yann Cheli, Mickaël Ohanna, Frédéric Luciano, Sandrine Marchetti, Stéphane Rocchi, Marie-Christine Birling, Marie-Françoise Avril, Nicolas Poulalhon, Thomas Luc, Corine Bertolotto
Journal: JNCI Journal of the National Cancer Institute (2016)

MITF encodes an oncogenic lineage-specific transcription factor in which a germline mutation ( MITFE318K ) was identified in human patients predisposed to both nevus formation and, among other tumor types, melanoma. The molecular mechanisms underlying the oncogenic activity of MITF E318K remained uncharacterized.Here, we compared the SUMOylation status of endogenous MITF by proximity ligation assay in melanocytes isolated from wild-type (n = 3) or E318K (n = 4) MITF donors. We also used a newly generated Mitf E318K knock-in (KI) mouse model to assess the role of Mitf E318K (n = 7 to 13 mice per group) in tumor development in vivo and performed transcriptomic analysis of the tumors to identify the molecular mechanisms. Finally, using immortalized or normal melanocytes (wild-type or E318K MITF, n = 2 per group), we assessed the role of MITF E318K on the induction of senescence mediated by BRAF V600E . All statistical tests were two-sided.We demonstrated a decrease in endogenous MITF SUMOylation in melanocytes from MITF E318K patients (mean of cells with hypoSUMOylated MITF, MITF E318K vs MITF WT , 94% vs 44%, difference = 50%, 95% CI = 21.8% to 67.2%, P = .004). The Mitf E318K mice were slightly hypopigmented (mean melanin content Mitf WT vs Mitf E318K/+ , 0.54 arbitrary units [AU] vs 0.36 AU, difference = -0.18, 95% CI = -0.36 to -0.007, P = .04). We provided genetic evidence that Mitf E318K enhances BRaf V600E -induced nevus formation in vivo (mean nevus number for Mitf E318K , BRaf V600E vs Mitf WT , BRaf V600E , 68 vs 44, difference = 24, 95% CI = 9.1 to 38.9, P = .006). Importantly, although Mitf E318K was not sufficient to cooperate with BRaf V600E alone in promoting metastatic melanoma, it accelerated tumor formation on a BRaf V600E , Pten-deficient background (median survival, Mitf E318K/+ = 42 days, 95% CI = 31 to 46 vs Mitf WT = 51 days, 95% CI = 50 to 55, P < .001). Transcriptome analysis suggested a decrease in senescence in tumors from Mitf E318K mice. We confirmed this hypothesis by in vitro experiments, demonstrating that Mitf E318K impaired the ability of human melanocytes to undergo BRAF V600E -induced senescence.We characterized the functions of melanoma-associated MITF E318K mutations. Our results demonstrate that MITF E318K reduces the program of senescence to potentially favor melanoma progression in vivo.
Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada.
Authors: Ketan Ghate, Ronald L. Burkes, Christine B. Brezden, Kevin M. Zbuk, Brandon Matthew Meyers, Oren Hannun Levine, Silvana Spadafora, Stephen Welch, Yoo-Joung Ko, Sukaina Davdani, Wilma M Hopman, Christopher M. Booth, Rachel Anne Goodwin, James Joseph Biagi
Journal: Journal of Clinical Oncology (2016)

6541 Background: Adjuvant chemotherapy (AC) for CC has been shown to increase survival in randomized trials. Analysis of time from curative surgery to AC (TTAC) has demonstrated diminished survival with increasing TTAC. Few studies have examined the reasons underlying delays in TTAC. Methods: Data was extracted from individual medical records of 1159 patients with CC who initiated AC at six large academic centers in Ontario between 2005-2012, including patient demographics, disease characteristics, treatment, readmissions, length of hospital stay, post-operative complications and time intervals between each step from surgery to AC. Patients were categorized into three Groups: (I) postoperative surgical /medical complications, (II) oncologist or patient-initiated delay, (III) no delays. Groups were compared using X2 test and one-way analysis of variance. A multivariable logistic regression model was used to determine factors associated with TTAC > 8 weeks. Results: In this 1159 patient cohort, 54% were male, with 48% under 65 and 19% over 74 years of age. There were 21%, 18% and 60% in Groups I, II, III respectively. TTAC in the 3 Groups was (I) 9.9±2.9 weeks, (II) 10.2±3.6 weeks, (III) 8.8±2.7 weeks (P < 0.01). In multivariate analysis, advanced age, postoperative complications, oncologist- or patient-initiated delays and need for central line placement were significant predictors for TTAC > 8 weeks. In group III (n = 615), age (65-74 years) (OR = 1.54; 95% CI, 1.05-2.26) and central line (OR = 2.01; 95% CI, 1.27-3.17) were significant factors for TTAC > 8 weeks. In group III, 59% had TTAC > 8 weeks. In the overall cohort, 65% had TTAC > 8 weeks even though 92% were deemed fit for chemotherapy at the original consultation. Conclusions: In major academic centers in Ontario, the majority of patients receive AC more than 8 weeks after surgery, even though most patients had no identifiable medical or surgical reasons for delay. This is likely due to health-system factors such as delay in referrals, consultations, central line placement and chemotherapy bookings. Local and regional quality improvement initiatives are needed to improve health-system delays and decrease TTAC.
Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients
Authors: Pier Luigi Zinzani, Sergio Storti, Alfonso Zaccaria, Luciano Moretti, Massimo Magagnoli, Enzo Pavone, Patrizia Gentilini, Luciano Guardigni, Marco Gobbi, Pier Paolo Fattori, Brunangelo Falini, Vito Michele Lauta, Maurizio Bendandi, Filippo Gherlinzoni, Amalia De Renzo, Francesco Zaja, Patrizio Mazza, Ettore Volpe, Monica Bocchia, Enrico Aitini, Maurizio Tabanelli, Giuseppe Leone, Sante Tura
Journal: Blood (1999)
Impact de l'insertion d'une prothèse oesophagienne métallique expansive sur la dénutrition dans le traitement palliatif du cancer de l'œsophage: étude de 116 malades
Authors: S Lecleire, F Di Fiore, M Antonietti, B Paillot, P Déchelotte, P Ducrotte, E Ben Soussan, P Michel
Journal: Endoscopy (2005)

Les prothèses œsophagiennes métalliques expansives (POME) sont actuellement employées en première intention dans le traitement palliatif des malades atteints d'un cancer de l'œsophage afin de pallier la dysphagie et de permettre une restitution de l'alimentation orale. Cependant, aucune étude n'a évalué l'impact de l'insertion d'une POME sur l'évolution nutritionnelle de ces malades. Le but de cette étude était donc d'évaluer rétrospectivement l'effet des POME sur l'évolution nutritionnelle et clinique des malades dans le traitement palliatif du cancer de l'œsophage.
miR-1224 inhibits cell proliferation in acute liver failure by targeting the antiapoptotic gene Nfib
Authors: Sanchari Roy, Heike Bantel, Franziska Wandrer, Anne Theres Schneider, Jeremie Gautheron, Mihael Vucur, Frank Tacke, Christian Trautwein, Tom Luedde, Christoph Roderburg
Journal: Journal of Hepatology (2017)
Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
Authors: Nae-Yun Heo
Journal: Clinical and Molecular Hepatology (2017)

See the Original "Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naÃ¯ve patients with chronic hepatitis B" on page 154.
Complimentary therapies – time to open our minds?
Authors: D O'Donovan, N Daly, M Brady, P MacMathuna
Journal: Endoscopy (2006)

Background: Irritable bowel syndrome (IBS) is a common disorder associated with significant a burden of illness and high healthcare utilisation. Management can be difficult and treatment often unrewarding. Public awareness and usage of complementary therapies is increasing; their use in the setting of IBS is attractive but unclear.
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Authors: Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Moshe Mittelman, Petra Muus, Stephen D. Nimer, Eva Hellström-Lindberg, Bayard L. Powell, Agnes Guerci-Bresler, Mikkael A. Sekeres, H. Joachim Deeg, Consuelo del Cañizo, Peter L. Greenberg, Jamile M. Shammo, Barry Skikne, Xujie Yu, Alan F. List
Journal: Journal of Hematology & Oncology (2017)

Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray’s test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. ClinicalTrials.gov NCT00065156 and NCT00179621
Noninvasive Nuclear SPECT Myocardial Blood Flow Quantitation to Guide Management for Coronary Artery Disease
Authors: Lung-Ching Chen, Bor-Hsin Jong, Sheng-Che Lin, Chi-Tai Ku, Ing-Jou Chen, Yen-Kung Chen, Bailing Hsu
Journal: Clinical Nuclear Medicine (2017)

Recently, myocardial blood flow quantitation with dynamic SPECT has been validated to enhance the detection of multivessel coronary artery disease (CAD) and conclude equivocal SPECT myocardial perfusion study. This advance opened an important clinical application to utilize the tool in guiding CAD management for area where myocardial perfusion tracers for PET are unavailable or unaffordable. We present a clinical patient with ongoing recursive angina who underwent multiple nuclear stress tests for a sequence of CAD evaluation in 26 months and demonstrated that SPECT myocardial blood flow quantitation properly guided CAD management to warrant patient outcome.
Impact of the 21-gene Recurrence Score assay on the adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes in an academic centre in Ontario.
Authors: Sofia Torres, Maureen E. Trudeau, Sonal Gandhi, Ellen Warner, Sunil Verma, Kathleen I. Pritchard, Teresa M. Petrella, Mark Hew-Shue, Calvin Chao, Andrea Eisen
Journal: Journal of Clinical Oncology (2016)

e12026 Background: The 21-gene Recurrence Score (RS) assay has been shown to be both prognostic and predictive of chemotherapy (CT) benefit in patients with node negative and node positive (N+), estrogen-receptor positive (ER+) early-stage breast cancer (EBC). Currently, the assay is only reimbursed by the provincial single payer Ontario Health Ministry for node-negative EBC. Methods: The primary objective of this prospective study is to characterize how the results of the RS assay impact the decision making processes of medical oncologists in an academic centre in Ontario by evaluating recommendations for adjuvant therapy for 70 patients with ER+, HER2-negative EBC and 1-3 positive lymph nodes. Secondary objectives are to characterize changes in the physician’s level of confidence in their recommendation, to determine whether the results of the RS affect patients’ treatment preferences and their level of confidence and to evaluate the actual treatment administered. Recruitment will be completed by the time of the ASCO meeting. Here we report the results for the first 50 patients, enrolled from October 2014 to December 2015. Results: Mean patients’ age was 61 (range: 41-84). Tumor size was ≤ 2 cm in 46% of patients, > 2-5 cm in 44% and > 5cm in 10%. Tumors were grade 1 in 24% of patients, grade 2 in 50% and grade 3 in 26%. RS was low ( < 18) in 52% of cases, intermediate (RS 18-30) in 38% and high ( ≥ 31) in 10%. Treatment recommendations changed in 35% of all evaluable patients (17 out of 48). The most significant change was in the group with a low RS ( < 18), with 48% of the recommendations changing from upfront CT pre-assay, to endocrine therapy only post-assay. Physicians’ confidence in the recommendations increased in 46% of cases and decreased in 12.5%. Patients’ confidence in their treatment choice increased in 65% of cases and decreased in 13%. Upfront CT was recommended to 75% of patients pre-assay, 43% ultimately received CT. Conclusions: The RS assay resulted in a substantial decrease in the number of node positive patients who would receive CT and in an increase of the physicians’ and patients’ confidence in the adjuvant treatment recommendations.
Value of intraoperative parathyroid hormone monitoring in papillary thyroid cancer surgery: Can it be used to guide the choice of operation methods?
Authors: Jinbiao Shang, Jiafeng Wang, Jialei Gu, Wendong Wang, Qianbo Han, Kejing Wang
Journal: Journal of Clinical Oncology (2015)

e17026 Background: To investigate the change of parathyroid hormone (PTH) in papillary thyroid carcinoma (PTC) surgery and assess the diagnostic value of decreased PTH in hypoparathyroidism after unilateral operation. Methods: A nonrandomized prospective study was conducted on patients with PTC undergoing total or near-total thyroidectomy plus central neck dissection (CND).Among 82 patients with PTC, intraoperative PTH was measured at the following time points: 1) before the skin incision was made;2) 10 minutes after lobectomy and ipsilateral CND; 3) 10 minutes after the end of bilateral operation (PTHb). Postoperative calcium and PTH levels were assayed daily until the patients were discharged. All patients were followed up at 1, 3, 6 months after surgery, at which time total calcium and ipsilateral PTH levels were measured. Results: Postoperative hypocalcemia was found in 42 patients (51.2%), in which 2 cases (2.4%) were permanent hypoparathyroidism. For patients undergoing bilateral CND, those whose tumor invasion proceeded beyond the thyroid capsule have a higher rate of postoperative hypoparathyroidism (p < 0.05). PTH level of hypoparathyroidism patients was lower than that of non-hypoparathyroidism patients from surgery to 6 months later (p < 0.05). When unilateral thyroidectomy and CND were completed, PTH level decreased by 47.06% in hypoparathyroidism patients, which was significantly higher than that in non-hypoparathyroidism patients (28.35%) (p < 0.001). ROC curve analysis showed that PTH level (AUC 0.806) and its decreasing degree (AUC 0.736) played predicting roles in assessing postoperative hypoparathyroidism (p < 0.001). Conclusions: For PTC surgery, PTH level and its decreasing degree played predicting roles in assessing postoperative hypoparathyroidism, which could be used as a reference for choosing operative methods.
L'entéroscopie à double ballon est supérieure à l'entéroscopie poussée dans le diagnostic et le traitement des hémorragies digestives explorées par capsule endoscopique
Authors: T Maniere, B Landi, V Pacault, M Simon, B Boboc, J Edery, JM Canard, F Bloch, R Jian, C Cellier
Journal: Endoscopy (2006)

L'entéroscopie double-ballon (EDB) est une technique récente d'exploration du grêle dont la rentabilité diagnostique a été peu étudiée. Le but de cette étude prospective était de comparer les résultats de l'EDB à ceux de l'entéroscopie poussée (EP) chez des patients ayant une hémorragie digestive avec une lésion visualisée par la capsule endoscopique (CE).
The buried bumper syndrome – a common, serious and preventable complication of PEG tube insertion
Authors: A Russell, J Keohane, O Crosbie, S O'Mahony
Journal: Endoscopy (2006)

Aims: Due to a recent increase in the number of cases of Buried Bumper Syndrome presenting to our services, we undertook a review of the cases between March 2004 and March 2005. We reviewed the aetiology and management of this well recognised complication.
Obesity Pathogenesis: An Endocrine Society Scientific Statement
Authors: Michael W Schwartz, Randy J Seeley, Lori M Zeltser, Adam Drewnowski, Eric Ravussin, Leanne M Redman, Rudolph L Leibel
Journal: Endocrine Reviews (2017)

Obesity is among the most common and costly chronic disorders worldwide. Estimates suggest that in the United States obesity affects one-third of adults, accounts for up to one-third of total mortality, is concentrated among lower income groups, and increasingly affects children as well as adults. A lack of effective options for long-term weight reduction magnifies the enormity of this problem; individuals who successfully complete behavioral and dietary weight-loss programs eventually regain most of the lost weight. We included evidence from basic science, clinical, and epidemiological literature to assess current knowledge regarding mechanisms underlying excess body-fat accumulation, the biological defense of excess fat mass, and the tendency for lost weight to be regained. A major area of emphasis is the science of energy homeostasis, the biological process that maintains weight stability by actively matching energy intake to energy expenditure over time. Growing evidence suggests that obesity is a disorder of the energy homeostasis system, rather than simply arising from the passive accumulation of excess weight. We need to elucidate the mechanisms underlying this "upward setting" or "resetting" of the defended level of body-fat mass, whether inherited or acquired. The ongoing study of how genetic, developmental, and environmental forces affect the energy homeostasis system will help us better understand these mechanisms and are therefore a major focus of this statement. The scientific goal is to elucidate obesity pathogenesis so as to better inform treatment, public policy, advocacy, and awareness of obesity in ways that ultimately diminish its public health and economic consequences.